Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients

Clinical Laboratory

Volumn 55, Issue 3-4, 2009, Pages 144-152

  Fassbender, Walter Josef ^a   Brandenburg, V ^b   Schmitz, S ^a   Sandig, D ^a   Simon, S A ^c   Windolf, J ^c   Stumpf, U C ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Chronic kidney disease (CKD); FGF 23; Phosphorus homeostasis; Renal osteodystrophy

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23;

ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PATHOGENESIS; PHOSPHATURIA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SECONDARY HYPERPARATHYROIDISM; STORAGE TEMPERATURE;

ADULT; AGED; BLOOD SPECIMEN COLLECTION; DATA INTERPRETATION, STATISTICAL; EDETIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEIN STABILITY;

EID: 65649086117     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Berndt TJ, Schiavi S, Kumar R. Phosphatonins and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289: F1170-F1182.
2. Cockroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
3. Collins MT, Lindsay JR, Jain A et al. Fibroblast Growth Factor-23 is regulated by 1α,25-Dihydroxyvitamin D. J Bone Miner Res 2005; 20: 1944-50.
4. Drezner MK, PHEX gene and hypophosphatemia. Kidney Int 2000; 57: 9-18.
5. Fukumoto S, Yamashita T, Fibroblast growth factor -23 is the phosphaturic factor in the tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 2002; 11: 385-9.
6. Goebel S, Seufert J, Ebert R, Duda G, Jakob F, Serum FGF 23 is elevated in the early phase of bone healing. Exp Clin Endocrinol Diabetes 2006; 114: S46.
7. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16(7): 2205-15.
8. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65(5): 1943-6.
9. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am See Nephrol 2005; 16(9): 2565-75.
10. Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T, Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005; 23 (6): 435-440.
11. Jan de Beur SM, Levine MA, Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 2002; 87: 2467-73.
12. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9(4): 336-9.
13. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64(6): 2272-9.
14. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69(3):531-7.
15. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ, FGF-23 and sFRP-4 in chronic kidney disease and postrenal transplantation. Nephron Physiol 2006; 104 (1): 23-32. Epub 2006 May 10.
16. Schiavi SC. Fibroblast Growth Factor 23: the making of a hormone. Kidney International 2006; 69: 425-7.
17. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004; 65(1): 1-14.
18. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypephosphatemia in vivo. Endocrinology 2002; 143(8): 3179-82.
19. Sommer S, Bernd T, Craig T, Kumar R, The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007; 103 (3-5): 497-503. Epub 2007 Jan 16.
20. Tenenhouse HS, Sabbagh Y, Novel Pi-regulating genes in the pathogenesis of renal Pi wasting disorders. Pflugers Arch 2002; 444: 317-26.